Patient Tissue Platform

Patient Tissue Platform

Open access protocols and data from patient-derived disease models

Efforts within patient-derived disease models at SGC aim to develop open access protocols and data from well-characterized human disease tissue, blood-derived assays and other model systems to profile chemical probes and chemogenomic libraries, guiding the identification of biomarkers and novel targets to drive drug discovery.

We focus on areas of high medical need in inflammatory diseases, fibrosis, oncology and neurodegenerative diseases. Specifically, our aim is to define and validate under-explored protein targets by profiling high-quality chemical and antibody probes in patient-derived cell assays of translational value, providing biomarkers, target engagement and phenotypic read-outs using disease-relevant models, including new complex cell co-culture systems.

IMI-funded EUbOPEN project

Our current network of collaborations consists of hospitals, research institutes and universities in Toronto and Montreal (Canada), Frankfurt (Germany) and Stockholm (Sweden). We also collaborate with a number of industrial partners to ensure the high relevance of our models and assays for translational medical studies to support early drug discovery efforts.

In the IMI-funded EUbOPEN project, we have profiled a number of chemical probes and chemogenomic compounds in colorectal cancer, multiple sclerosis and non-alcoholic fatty liver disease (NASH).

Read more about the EUbOPEN project

IMI-funded ULTRA-DD project

As part of the past IMI-funded ULTRA-DD project, focusing on autoimmune and inflammatory conditions, we identified new targets for disease modulation in systemic lupus erythematosus, myositis, systemic sclerosis, ankylosing spondylitis and Dupuytren’s disease (hand fibrosis).

Read more about the ULTRA-DD project.